Literature DB >> 11425684

Effect of varying the optical zone diameter on the results of hyperopic laser in situ keratomileusis.

J M Davidorf1, F Eghbali, T Onclinx, R K Maloney.   

Abstract

PURPOSE: To compare the predictability and safety of laser in situ keratomileusis (LASIK) for low to moderate spherical hyperopia using different ablation zone diameters.
DESIGN: Retrospective, nonrandomized, comparative trial. PARTICIPANTS: Forty-nine eyes that underwent hyperopic LASIK. INTERVENTION: Two surgeons (JMD, RKM) performed hyperopic LASIK using the VISX STAR S2 excimer laser (VISX, Inc., Sunnyvale, CA) and the Bausch & Lomb Hansatome microkeratome (Chiron Vision, Irvine, CA) using ablation zone diameters of 5 x 9 mm, 5.5 x 8.5 mm, or 6 x 9 mm (the first number represents the optical zone diameter and the second number represents the diameter of the outer border of the ablation zone). MAIN OUTCOME MEASURES: Refractive and visual outcomes at 3 to 6 months after surgery were analyzed. Groups were compared for deviations from targeted spherical equivalent, uncorrected visual acuity, and loss of best spectacle-corrected visual acuity (BSCVA).
RESULTS: The mean intended hyperopic correction was +2.48 +/- 1.13 diopters (D; 0.63-5.50 D). There were 16 eyes in the 5 x 9-mm group, 15 eyes in the 5.5 x 8.5-mm group, and 18 eyes in the 6 x 9-mm group. On average, the 5 x 9-mm group achieved 97% of the programmed correction, the 5.5 x 8.5-mm group achieved 104%, and the 6 x 9-mm group achieved 112% of the programmed correction. The tendency toward overcorrection in the 6 x 9-mm group compared with the 5 x 9-mm group was statistically significant (P < 0.05). The incidence of one line loss of BSCVA was greatest in the 5 x 9-mm group (19%) and lowest in the 6 x 9-mm group (6%). These differences were not statistically significant. No eyes experienced a loss of two or more lines of BSCVA at last examination.
CONCLUSIONS: Hyperopic LASIK using the VISX STAR is safe and effective using different ablation zone diameters. There appears to be an increased tendency toward overcorrection with progressively larger optical zone diameters.

Entities:  

Mesh:

Year:  2001        PMID: 11425684     DOI: 10.1016/s0161-6420(01)00588-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  The surgical correction of moderate hypermetropia: the management controversy.

Authors:  C N McGhee; S Ormonde; T Kohnen; M Lawless; A Brahma; I Comaish
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

2.  Conductive keratoplasty: a radiofrequency-based technique for the correction of hyperopia.

Authors:  Marguerite B McDonald
Journal:  Trans Am Ophthalmol Soc       Date:  2005

3.  Predictability and stability of refraction with increasing optical zone diameter in hyperopic LASIK.

Authors:  Mostafa A El-Helw; Ahmed M Emarah
Journal:  Clin Ophthalmol       Date:  2010-05-14

4.  Long-Term Followup of Laser In Situ Keratomileusis for Hyperopia Using a 213 nm Wavelength Solid-State Laser.

Authors:  Carmina Franz G Quito; Archimedes Lee D Agahan; Raymond P Evangelista
Journal:  ISRN Ophthalmol       Date:  2013-03-03

5.  Assessment of refractive outcome of femtosecond-assisted LASIK for hyperopia correction.

Authors:  Mohamed Tarek El-Naggar; Dikran Gilbert Hovaghimian
Journal:  Electron Physician       Date:  2017-03-25

6.  Role of percent peripheral tissue ablated on refractive outcomes following hyperopic LASIK.

Authors:  George Fatseas; Fiona Stapleton; Patrick Versace
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

7.  Lasik as a Solution for High Hypermetropia.

Authors:  Alma Biscevic; Ajla Pidro; Melisa Ahmedbegovic Pjano; Senad Grisevic; Nina Ziga; Maja Bohac
Journal:  Med Arch       Date:  2019-06

8.  Femtosecond-LASIK outcomes using the VisuMax®-MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery.

Authors:  Bogdana Tăbăcaru; Horia Tudor Stanca; Ruxandra Angela Pîrvulescu; Simona Stanca; Ciprian Danielescu; Mihnea Munteanu; Cosmin Roșca; Adrian Cosmin Teodoru
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.